Point72 Asia Singapore Pte. Ltd. Has $408,000 Stock Holdings in Emergent BioSolutions Inc. (NYSE:EBS)

Point72 Asia Singapore Pte. Ltd. increased its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 408.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 42,712 shares of the biopharmaceutical company’s stock after buying an additional 34,311 shares during the period. Point72 Asia Singapore Pte. Ltd.’s holdings in Emergent BioSolutions were worth $408,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of EBS. Covestor Ltd lifted its position in Emergent BioSolutions by 5,458.5% during the fourth quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 2,893 shares during the last quarter. Northern Trust Corp lifted its holdings in Emergent BioSolutions by 2.6% during the 4th quarter. Northern Trust Corp now owns 145,889 shares of the biopharmaceutical company’s stock worth $1,395,000 after purchasing an additional 3,692 shares during the last quarter. LPL Financial LLC boosted its stake in Emergent BioSolutions by 34.5% in the 4th quarter. LPL Financial LLC now owns 15,120 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 3,875 shares during the period. Federated Hermes Inc. grew its holdings in Emergent BioSolutions by 2.2% in the 4th quarter. Federated Hermes Inc. now owns 277,810 shares of the biopharmaceutical company’s stock valued at $2,656,000 after buying an additional 6,058 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in Emergent BioSolutions during the 4th quarter worth $63,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Emergent BioSolutions in a research report on Tuesday, April 1st. StockNews.com cut shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Wednesday, March 5th.

Emergent BioSolutions Stock Performance

EBS opened at $5.51 on Friday. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. Emergent BioSolutions Inc. has a 52-week low of $4.02 and a 52-week high of $15.10. The firm has a market cap of $299.40 million, a P/E ratio of -1.34 and a beta of 2.09. The business’s fifty day moving average is $5.13 and its 200-day moving average is $7.82.

Emergent BioSolutions (NYSE:EBS) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.22. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The firm had revenue of $222.20 million for the quarter, compared to the consensus estimate of $218.50 million. Sell-side analysts expect that Emergent BioSolutions Inc. will post -0.63 EPS for the current fiscal year.

Emergent BioSolutions announced that its board has authorized a share repurchase program on Monday, March 31st that authorizes the company to buyback $50.00 million in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to buy up to 19% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling at Emergent BioSolutions

In other news, Director Neal Franklin Fowler sold 35,000 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total value of $204,050.00. Following the completion of the transaction, the director now owns 101,100 shares of the company’s stock, valued at approximately $589,413. This represents a 25.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.20% of the company’s stock.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.